Award-Winning Stargazing Guide Star Walk Now Available on Android

Posted on by

Alexandria, VA (PRWEB) December 24, 2013

Vito Technology has announced the release of their award-winning astronomy guide Star Walk for Android. Star Walk is an educational augmented reality app for spotting over 200,000 stars, planets, constellations, satellites and galaxies in the night sky. The Android version includes everything users need to navigate through the night sky, learn about any object, travel in time to a specific date and much more.

Star Walk is a handy astronomy guide that shows celestial objects (stars, constellations, satellites, etc.) in the exact positions on the sky above, providing comprehensive information about them. It helps anyone even remotely interested in astronomy find their way across the sky, determine where to look for any chosen object, rewind or fast-forward time to see how celestial bodies move. It inspires curiosity about the Universe and helps understand amazing cosmic phenomena.

The main and the most impressive feature of the app is called Star Spotter. It turns on automatically when users hold their device over their head towards the sky and starts following their motions as they pan around. The image on the device will correspond the actual star map for that location. If the device has a back-facing camera, it can be used in the Augmented Reality mode to overlay actual sky images with Star Walk map.

Having looked around, users might want to learn more information on something they find interesting. They can just tap the object and an (i) will appear next to its name. Star Walk information database was built in collaboration with European Space Agency (ESA) to provide users with most accurate data and stunning pictures.

App Highlights:

Language Support:

English, Arabic, Chinese, Dutch, French, German, Italian, Japanese, Korean, Russian, Spanish

Device Requirements:

Android 4.0 120 MB

Continued here:

Award-Winning Stargazing Guide Star Walk Now Available on Android

‘Bangalore aerospace park can touch $20bn revenue’

Posted on by

The author has posted comments on this articleAnshul Dhamija, TNN | Dec 25, 2013, 01.56AM IST BANGALORE: The aerospace industry in Bangalore has the potential to achieve $20 billion in revenues over the next 10 to 15 years if the state government is able to nurture an ecosystem that attracts global companies, said the India head of UTC Aerospace Systems (UTCAS), Chris Rao.

Part of the $64 billion US-based United Technologies, UTCAS is the largest MNC aerospace manufacturer in India and was part of the task force that helped bring out the country's first aerospace policy in Karnataka.

"Bangalore is the aerospace capital of this country. However, the government has to attract companies to invest here," said Rao, VP, UTCAS.

Bangalore has the right talent pool, which has been nurtured over the years by public sector enterprises such as HAL, DRDO and ISRO.

Rao said, "If they (government) go about the project (aerospace park) by just selling land parcels then they aren't developing an ecosystem concept. You would get speculators (buying into real estate) rather than industry guys and that's where it's at right now." He added that for tier I companies to set up shop, an aerospace SEZ would have to have tier III and IV suppliers as well as academic and training institutions.

"We are telling the government to develop the park as an ecosystem. Give it to an ecosystem developer, not a real estate developer because that's where the problem starts. Industry should invest in technology and people, not in land and infrastructure," said Rao.

At present, the aerospace industry is concentrated in the US and Europe. With most companies looking to expand outside of these two markets, India and China are gaining a lot of attention. However, China has been facing concerns over intellectual property rights, so aerospace companies are looking keenly at India.

UTCAS, which got a foothold in to India through its global $19 billion acquisition of Goodrich two years ago, manufactures evacuation slides, lighting systems, cargo systems, seating systems, sensors and integrated systems, and electrical power systems for Airbus and Boeing aircraft. "On an average about 60% of the global production of these products are done out of Bangalore," said Rao.

UTCAS employs close to 2,000 people and has outgrown its 700,000 sqft facility located in the IT hub of Whitefield. "We want to reach a stage where we can design, develop, manufacture and support products from India. There are still areas in which we need to shore up our competencies, especially on the design side," added Rao.

Read this article:

‘Bangalore aerospace park can touch $20bn revenue’

Hackensack High School (NJ) Football Home – MaxPreps.com

Posted on by

Updates From This Month Team rankings updated on: 12/21/2013 11:25 PM

MaxPreps' football rankings have been updated. Hackensack's national rank has moved -25 and their state rank has moved -3. View Rankings

Big North - Freedom league recap: 12/3/13 Read Article

Congratulations to #24 Aaron Guzman for being selected as the Offensive Player of the Game.

21 carries for 192 yards and 3 TDS

Hackensack's stats have been entered for the Win @ Teaneck on 11/28/2013. Box Score Stats by Game Stats by Player

Hackensack's stats have been entered for the Loss @ Passaic County Tech on 11/15/2013.This game was part of the 2013 New Jersey Boys State Football Playoff Brackets: NJSIAA - North 1 Group 5. Box Score Stats by Game Stats by Player Tournament Leaders

The Hackensack Comets football team won Thursday's away non-conference game against Teaneck by a score of 35-12. Box Score

Have a pro photographer take high-quality photos to receive exposure on MaxPreps, ability to order print and digital downloads and more. Click the link to learn more on how to get a pro photographer out to your game. Read Article

Big North - Liberty league recap: 11/19/13 Read Article

Link:

Hackensack High School (NJ) Football Home - MaxPreps.com

Comets Win Streak Grows to Four Games

Posted on by

December 22, 2013 - Major Indoor Soccer League (MISL) Missouri Comets INDEPENDENCE, MO (December 22, 2013) - A 24-13 victory over the visiting St. Louis Ambush extends the Missouri Comets winning streak to four games. The win also gives the Comets a 3-0 lead in the I-70 Series between the cross-state rivals. Comets' midfielder Bryan Perez led all scorers with an impressive 7 points for the night with 2 goals and three assists, while John Sosa was right behind him with six points. 3,102 fans braved the snow and cold temperatures to watch the Comets go to 4-1 on the season, only one game back of first place Syracuse Silver Knights.

Perez was the first to score for the Comets; three other goals from Ramone Palmer, Stefan St. Louis, and Byron Alvarez would complete the opening shutout quarter for the home team. Although St. Louis is new to the Major Indoor Soccer League, the rivalry between these two teams goes back a long way. The competitive spirit was evident right away. Both teams combined for 16 fouls in the first half.

The Ambush would finally get on the board early in the second quarter with a three-point goal from Mike Mesle. St. Louis forward Odaine Sinclair managed to dribble past a sprawling Danny Waltman four minutes later to get the Ambush within three points, but the Comets' Byron Alvarez, Perez and Lucas Rodriguez scored goals in the second quarter to take their side into half with a 14-7 lead.

The two teams traded goals in the third quarter, with Robert Palmer knocking one in for the Comets and Jeff DiMaria finding the net for the Ambush. However, the action heated up even more with four players seeing the inside of the penalty box in the period.

St. Louis tried to climb back into the game in the fourth period, but John Sosa and Leo Gibson each scored and Vahid Assadpour chipped in with two of his own to put the game out of reach. The Comets had eight different scorers tonight as the MISL's leading offense led to the team to a 24-13 victory.

The Comets are home again on December 28th to take on the league-leading Syracuse Silver Knights at 7:35p.m. CT. The team will be welcoming media from newspaper, TV, Radio and the internet for the annual Comets Media Game at halftime.

Discuss this story on the Major Indoor Soccer League message board... Digg this story Add to Del.icio.us

See original here:

Comets Win Streak Grows to Four Games

Comets Corner: On the Mask

Posted on by

December 23, 2013 - American Hockey League (AHL) Utica Comets For most professional goalies, a mask is not just a mask - it's an opportunity to express themselves and show the things that are most important in their lives. This past week, we sat down with Comets goaltenders Joacim Eriksson and Joe Cannata to learn about the designs on their current goalie masks.

Designed by Swedish artist David Gunnarsson and completed this past July, Eriksson's mask sticks with the green and blue color palate of the Canucks and Comets. On the top of his mask, he has a blue killer whale bearing its teeth. On the right side, Gunnarsson placed the Canucks orca, "Johnny Canuck," along with the faded green seal of the first team Eriksson ever played for, Hedusanda IF. The chin of the mask shows Eriksson's nickname - Jocke - highlighted with a white background and grey writing. This is the only area on the mask where white is the predominant color. The back of the mask features the Swedish flag in its traditional colors, blue and yellow, along with the initials "JL," which stand for one of Eriksson's dear friends who passed away in a car accident. "I really wanted him to be on it," Eriksson stated.

Eriksson is no stranger to custom masks, as this is his fifth (he had four while playing in Sweden). Despite being extremely happy with his current mask, he excitedly explained that he plans to get a new mask in the next couple of months. "I want it to have a dragon and a warrior," he described. "With flames...I think it's going to be really cool." Eriksson plans to keep the same color scheme. Eriksson will return to David Gunnarsson for his next design.

Much like Erkisson, Comets goaltender Joe Cannata also has a green and blue themed mask. Designed a mere three months ago by artist Marlene Ross, Cannata's mask features the Canucks logo on top in the traditional colors. "I like that logo because it's also on the shoulders of the Comets jerseys, and if I go up to the Canucks, it will mean something up there," Cannata explained. The logo is breaking out of ice to symbolize the ice the team plays on. The sides of his mask simply show the breaking ice heading towards the front. On the chin, Cannata has his name placed in the Massachusetts license plate, so he always remembers where he came from. The back of Cannata's mask features "MC," which stands for Merrimack College, where Cannata played for four years before entering the pro league.

"The favorite part of my mask has to be colors," Cannata answered. "The colors are a little brighter, so it tends to stick out on the ice. Marlene did a great job." When discussing past and future masks, Cannata explained that he looks forward to the summers, where he plans out his design for the next season.

Discuss this story on the American Hockey League message board... Digg this story Add to Del.icio.us

Read the original here:

Comets Corner: On the Mask

‘Comets of the Centuries’: 500 Years of the Greatest Comets Ever Seen

Posted on by

When Comet ISON was discovered and a preliminary orbit for it was worked out, it was initially announced that it could be the "comet of the century."

Of course, the 21st century is only 12 years old (from 2001) and ISON turned out to be a dud. But out there in the far recesses of space there is certainly some unknown comet worthy of such an honorific title that will ultimately put on a unique and memorable show sometime during this century.

There will always be bright and spectacular comets, but in each century there is always one that will stand above the others. Below I provide my own list of the five most spectacular comets that have appeared in each century starting from the 16th and running through the 20th century.

Take note that four of these five dazzlers appeared in the latter half of their century and that the average time between appearances amounts to 97 years. Considering that Comet Ikeya-Seki passed by in 1965, the next prospective "Comet of the Century" might not appear according to our small sampling until maybe 2029 at the earliest and maybe not even until the next century (in 2103!). [Incredible Photos of Comet ISON]

Then again, stupendously bright comets are totally unpredictable and can suddenly appear at almost any time.

Greatest Comet of the 16th Century: The Great Comet of 1577

This comet passed to within 16.7 million miles (26.9 million kilometers) of the sun on Oct. 27, but was not sighted until five days later, when it was described in an account from Peru as an exceptionally brilliant object. Contemporary descriptions note that it was seen through the clouds like the moon.

By Nov. 8, it was reported by Japanese observers as a "broom star," appearing "as bright as the moon" with a white tail spanning over 60 degrees (your clenched fist held at arm's length measures 10 degrees). The famous astronomer Tycho Brahe first saw the comet as a reflection in his garden fish pond on Nov. 13, and likened its brightness to Venus. The comet was still as bright as zero magnitude inDecember before it finally dropped below the limit of naked-eye visibility on Jan. 26, 1578. (Magnitude is a measure of a celestial object's brightness, with smaller numbers corresponding to brighter objects.)

Greatest Comet of the 17th Century: The Great Comet of 1680

The great excitement that accompanied the first announcement of the discovery of Comet ISON was that initially its orbit appeared strikingly similar to this spectacular 17th century comet; it was hoped that perhaps ISON was either a return of this amazing object, or at the very least a large fragment. But later calculations showed this was not so.

Read the rest here:

'Comets of the Centuries': 500 Years of the Greatest Comets Ever Seen

Comets beat AHL rival Abbotsford again with shutout

Posted on by

UTICA Thanks to a solid performance between the pipes by Utica goaltender Joacim Eriksson, the Comets rolled over the Abbotsford Heat for the second time in three nights as they earned a 3-0 victory at the Utica Memorial Auditorium on Friday.

Eriksson earned the second shutout of his American Hockey League career after the Swede turned aside all 21 shots he faced and his two shutouts on the season moved him into a tie for second in the league.

He is now 4-0-0-0 in his last four starts, with a 1.48 goals-against average and a .953 save percentage.

Kellan Lain, Alexandre Grenier and Benn Ferriero each found the scoresheet for the Comets, who gave their head coach Travis Green a victory on his 43rd birthday.

For the second straight game, the Comets struck first as Lain used a nifty move to get past a Heat defender, and in all alone on netminder Joni Ortio. From there, Lain beat Ortio with a slick back hand deke, to give the Comets a 1-0 lead. Lain, who now has goals in three straight games, also picked up his fourth in six games against the Heat this season. Linemate Brandon DeFazio had the primary helper, while defenseman Peter Andersson picked up an assist for the third game in a row.

The Comets doubled their advantage with just 3:11 left in the period as Alexandre Grenier scored a highlight reel goal on the power play.

Ortio finished with 20 saves on 22 shots.

With the win, Utica remained undefeated on their current homestand as they moved to 3-0 in front of an announced crowd of 3,225.

The Comets, who have their next four on home ice as well, have also won their last four overall at The Aud.

Utica was also able to score a power-play goal for the fifth straight game on home ice, which ties their longest streak of the season.

More:

Comets beat AHL rival Abbotsford again with shutout

What Is Psoriasis?

Posted on by

What is Psoriasis?

Psoriasis (sore-EYE-ah-sis) is a medical condition that occurs when skin cells grow too quickly. Faulty signals in the immune system cause new skin cells to form in days rather than weeks. The body does not shed these excess skin cells, so the cells pile up on the surface of the skin and lesions form.

What are the signs and symptoms? The lesions vary in appearance with the type of psoriasis. There are five types of psoriasis: Plaque, guttate, pustular, inverse, and erythrodermic. About 80% of people living with psoriasis have plaque (plak) psoriasis, also called psoriasis vulgaris. Plaque psoriasis causes patches of thick, scaly skin that may be white, silvery, or red. Called plaques (plax), these patches can develop anywhere on the skin. The most common areas to find plaques are the elbows, knees, lower back, and scalp.

Psoriasis also can affect the nails. About 50% of people who develop psoriasis see changes in their fingernails and/or toenails. If the nails begin to pull away from the nail bed or develop pitting, ridges, or a yellowish-orange color, this could be a sign of psoriatic (sore-EE-at-ic) arthritis. Without treatment, psoriatic arthritis can progress and become debilitating. It is important to see a dermatologist if nail changes begin or joint pain develops. Early treatment can prevent joint deterioration.

What causes psoriasis? Psoriasis is not contagious. You cannot get psoriasis from touching someone who has psoriasis, swimming in the same pool, or even intimate contact. Psoriasis is much more complex.

So complex, in fact, scientists are still studying what happens when psoriasis develops. We know that the persons immune system and genes play key roles. In studying the immune system, scientists discovered that when a person has psoriasis, the T cells (a type of white blood cell that fights unwanted invaders such as bacteria and viruses) mistakenly trigger a reaction in the skin cells. This is why you may hear psoriasis referred to as a T cell-mediated disease.

This reaction activates a series of events, causing new skin cells to form in days rather than weeks. The reason T cells trigger this reaction seems to lie in our DNA. People who develop psoriasis inherit genes that cause psoriasis. Unlike some autoimmune conditions, it appears that many genes are involved in psoriasis.

Scientists are still trying to identify all of the genes involved. One of the genes that has been identified is called PSORS1 (SORE-ESS-1). This is one of several genes that regulates how the immune system fights infection.

Scientists also have learned that not everyone who inherits genes for psoriasis gets psoriasis. For psoriasis to appear, it seems that a person must inherit the right mix of genes and be exposed to a trigger. Some common triggers are a stressful life event, skin injury, and having strep throat. Many people say that that their psoriasis first appeared after experiencing one of these. Triggers are not universal. What triggers psoriasis in one person may not cause psoriasis to develop in another.

Who gets psoriasis? People worldwide develop psoriasis. In the United States, nearly 7.5 million people have psoriasis and about 150,000 new cases are diagnosed each year. Studies indicate that psoriasis develops about equally in males and females. Research also shows that Caucasians develop psoriasis more frequently than other races. A study conducted in the United States found the prevalence was 2.5% in Caucasians and 1.3% in African Americans.

See the article here:

What Is Psoriasis?

Sandoz begins Phase III clinical trial for biosimilar adalimumab

Posted on by

Novartis International AG / Sandoz begins Phase III clinical trial for biosimilar adalimumab . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Holzkirchen, Germany, December 19, 2013 - Sandoz, the global leader in biosimilars, announced it has initiated a Phase III clinical trial with its biosimilar version of adalimumab (AbbVie's HUMIRA) - the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn's disease. This is Sandoz's eighth Phase III trial initiation across six compounds.

The aim of the study is to demonstrate equivalent efficacy, similarity, and immunogenicity of the Sandoz product versus HUMIRA in patients with moderate to severe plaque-type psoriasis. Sandoz is working closely with physicians and patients on this global trial, which spans 12 countries across Europe, the United States and Asia including Japan.

Psoriasis affects approximately 3% of the world's population[1]. There is significant unmet need in psoriasis with between nine and 30 percent of patients with severe psoriasis receiving no treatment at all[2]. "Because psoriasis is a chronic condition that often requires lifelong management, treatment can become a significant financial strain for many patients and healthcare systems," said Professor Dr. Peter van de Kerkhof, Chairman of the Department of Dermatology at the Radboud University Nijmegen Medical Centre in The Netherlands and President of the International Psoriasis Council (IPC) Board of Directors. "A high-quality and clinically proven biosimilar version of adalimumab could play a meaningful role in alleviating cost burdens related to this disease."

"This latest advancement in our pipeline represents our unwavering commitment to expanding patient access to biologics - particularly in disease areas where there is a significant need for more treatment choices," said Mark McCamish, M.D., Ph.D., and Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz. "We look forward to bringing a high-quality and affordable biosimilar version of adalimumab to individuals around the world living with psoriasis and other debilitating autoimmune diseases such as rheumatoid arthritis."

"Adalimumab will be a key building block in our growing Immunology portfolio, which includes other biosimilar candidates currently in Phase III trials such as etanercept (Amgen's Enbrel) and rituximab (Roche's Rituxan/MabThera)," said Ameet Mallik, Sandoz' Head of Biopharmaceuticals and Oncology Injectables. "This key development milestone further strengthens our global leadership in biosimilars and builds on our industry-leading pipeline."

Sandoz is the pioneer in biosimilars and the global market leader with over 50 percent market segment share of all biosimilars approved in the highly regulated markets of U.S., Canada, Europe, Japan and Australia. All three Sandoz biosimilars occupy the #1 biosimilar position (volume market share) in their respective categories. Sandoz biosimilars are sold in over 50 countries and have generated over 100 million patient exposure days in experience.

Disclaimer This press release contains forward-looking statements that can be identified by terminology such as "begins," "will," "aim," "can," "could," "commitment," "look forward to," "growing," or similar expressions, or by express or implied discussions regarding potential new biosimilar products; or regarding potential future sales of biosimilar products. Such forward-looking statements reflect the current views of the Novartis Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new biosimilar products will be submitted or approved for sale in any market. Nor can there be any guarantee that Sandoz will achieve any particular financial results from its biosimilar products. In particular, management's expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including the potential outcome of the FDA's biosimilars regulatory process; unexpected clinical trial results, including additional analyses of existing clinical data or unexpected new clinical data; unexpected product manufacturing issues; government, industry, and general public pricing pressures; competition in general; unexpected development difficulties; unexpected patent litigation outcomes; the impact that the foregoing factors could have on the values attributed to the Group's assets and liabilities as recorded in the Group's consolidated balance sheet; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Sandoz

Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the rapidly growing generics industry. Sandoz employs over 26,000 employees in more than 140 countries, offering broad range of over 1,000 high-quality, affordable products that are no longer protected by patents. With USD 8.7 billion in sales in 2012, Sandoz holds the #1 position globally in biosimilars as well as generic injectables, ophthalmics, dermatology and antibiotics as well as strong positions in the treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003 , Sandoz has benefitted from strong growth of its acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).

Follow this link:

Sandoz begins Phase III clinical trial for biosimilar adalimumab

Psoriasis – Wikipedia, la enciclopedia libre

Posted on by

La psoriasis (AFI:[soja.sis], del griego , picor) es una enfermedad inflamatoria crnica de la piel que produce lesiones escamosas engrosadas e inflamadas, con una amplia variabilidad clnica y evolutiva. No es contagiosa, aunque s puede ser hereditaria, es ms probable que la hereden los hombres que las mujeres.

Puede afectar a cualquier parte de la piel, frecuentemente a las zonas de codos, rodillas, cuero cabelludo, abdomen y espalda. No es raro que produzca afectacin de las uas.Esto se conoce como psoriasis ungueal. Las uas pueden ser la nica zona afectada al principio de la psoriasis. En ocasiones produce complicaciones como la artritis psorisica.

La clasificacin ms utilizada se organiza segn los sntomas, los tipos de lesiones cutneas y la gravedad general del cuadro. Es la clasificacin ms til para la eleccin de su tratamiento y para el conocimiento del pronstico de la enfermedad en cada paciente. La clasificacin est detallada en el apartado de manifestaciones clnicas. En la antigedad era falsamente diagnosticada como lepra, debido a la similitud de sintomatologa.

Se estima que entre un 1 y un 3% de la poblacin sufre de psoriasis.[1][2] Si bien puede aparecer a cualquier edad, suele hacerlo entre los 15 y los 35 aos, con un pico mximo de incidencia en la segunda dcada. Afecta por igual a ambos sexos, aunque es ms precoz en mujeres y en personas con antecedentes familiares. Por otro lado, no existe relacin entre psoriasis y cncer de piel (no maligniza).

La causa de la psoriasis es una velocidad anormalmente alta de mitosis en las clulas epidrmicas que se puede relacionar con una sustancia transportada en la sangre, un defecto en el sistema inmune.

Se cree que no tiene una causa nica, sino multifactorial, en individuos con predisposicin gentica a padecerla y que puede ser desencadenada o exacerbada por diversos factores ambientales.

La herencia de esta enfermedad es posiblemente polignica. Se ha demostrado una importante agregacin familiar,[3] el aumento de concordancia en gemelos monocigotos y la asociacin a determinados HLA.

En este sentido, se asocia la predisposicin a psoriasis con los antgenos HLA-CW6, y HLA-DR7. Adems, existe correlacin entre el tipo clnico de psoriasis y otros antgenos HLA. Por ejemplo, el HLA-B17 se asocia a un inicio ms precoz y un curso ms grave, y el HLA-B27 est relacionado con la forma pustulosa generalizada.

Entre otros, cabe destacar:

Aunque est poco esclarecida, hay dos hechos bsicos: la hiperplasia epidrmica por un aumento de la poblacin germinativa, y el infiltrado inflamatorio de la dermis. La inflamacin viene mediada por el Linfocito T CD4+ que libera (junto al queratinocito) citocinas proliferativas, que estimulan la proliferacin de las clulas epidrmicas. La respuesta inflamatoria es de tipo celular, frente a un autoantgeno an desconocido, o frente a un superantgeno estreptoccico en el caso de la psoriasis en gotas postinfecciosa.

Link:

Psoriasis - Wikipedia, la enciclopedia libre

World Nomads Travel Insurance – Explore Your Boundaries

Posted on by

Country of residence I am a permanent resident of... Andorra Antarctica Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Bermuda Bhutan Bolivia Bonaire, Saint Eustatius and Saba Bosnia Botswana Brazil Brunei Darussalam Bulgaria Cambodia Cameroon Canada Cayman Islands Chile China Colombia Costa Rica Croatia Curaao Cyprus Czech Republic Denmark Domninican Republic Ecuador Egypt El Salvador Estonia Falkland Islands Fiji Finland France French Polynesia Georgia Germany Gibraltar Greece Greenland Guadeloupe Guam Guatemala Honduras Hong Kong Hungary Iceland India Indonesia Iran Ireland Israel Italy Jamaica Japan Kazakhstan Kenya Kuwait Kyrgyzstan Laos Latvia Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malaysia Maldives Malta Mauritius Mexico Moldova Monaco Mongolia Morrocco Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Romania Russia Samoa San Marino Saudi Arabia Singapore Sint Maarten Slovakia Slovenia Solomon Islands South Africa South Korea Spain Sri Lanka Sweden Switzerland Taiwan Tajikistan Thailand Tonga Trinidad and Tobago Tunisia Turkey Turks & Caicos Islands Turkmenistan Ukraine United Arab Emirates United Kingdom Uruguay USA Uzbekistan Vanuatu Venezuela Vietnam Virgin Islands (British)

Destination region select a region Worldwide - inc. USA, Canada & Japan Worldwide - ex. USA, Canada & Japan

Policy start date? Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 2010 2011

Policy duration 2 days 3 days 5 days 1 week 2 weeks 1 month 2 months 3 months 4 months 5 months 6 months 7 months 8 months 9 months 10 months 11 months 12 months You can extend while you are away

Policy type Single Family

Read more from the original source:

World Nomads Travel Insurance - Explore Your Boundaries

Top award for Malta Corinthia

Posted on by

Corinthia Hotels properties in Malta, Russia, Sudan and Hungary were among the worlds travel elite to receive top honours at the World Travel Awards (WTA) Grand Final Gala Ceremony 2013 held in Doha, Qatar, on 30th November.

The Corinthia Palace Hotel & Spa was voted Maltas Leading Hotel for the fifth consecutive year, whereas the Corinthia Hotel St Petersburg was named Russias leading Conference Hotel for the second year running. The other two awards went to Corinthia Hotel Khartoum as Sudans Leading Hotel and the exclusive residences within the Corinthia Hotel Budapest as Hungarys Leading Hotel Residences.

Celebrating its 20th anniversary and hailed as The Oscars of the Travel Industry by the global media, World Travel Awards is acknowledged across the globe as the ultimate travel accolade, and highlights and rewards those travel brands that have made the greatest contribution to the industry over the past year. A packed delegation of VIPs, senior tourism figures and international media travelled from around the globe to attend the event.

Underlining the depth and quality of the travel and tourism sector across the globe, Graham E. Cooke, President and Founder, World Travel Awards said: We are proud to have held these Awards in Doha, showing our continued support for innovative development of tourism in this region. The Grand Final is a very competitive evening for our World Travel Awards nominees from all over the world, and these particular winners continue to serve as an example of the most luxurious and innovative brands with unique hospitality products and services. Tonights recipients strive to set the highest possible bar to raise the standards of excellence in travel and tourism and they carry these accolades into 2014 with pride and passion.

Visit link:

Top award for Malta Corinthia